These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

114 related articles for article (PubMed ID: 2441913)

  • 21. Different patterns of disease in two inbred mouse strains infected with a clone of Leishmania mexicana amazonensis.
    Barral-Netto M; Cardoso SA; Barral A
    Acta Trop; 1987 Mar; 44(1):5-11. PubMed ID: 2884839
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Induction of cellular and humoral responses by autoclaved and heat-killed antigen of Leishmania donovani in experimental visceral leishmaniasis.
    Nagill R; Mahajan R; Sharma M; Kaur S
    Parasitol Int; 2009 Dec; 58(4):359-66. PubMed ID: 19638322
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Comparative study of DNA vaccines encoding various antigens against Leishmania mexicana.
    Dumonteil E; Andrade-Narvarez F; Escobedo-Ortegon J; Ramirez-Sierra MJ; Valencia-Pacheco G; Flores-Serrano A; Canto-Lara S; Arjona-Torres A
    Dev Biol (Basel); 2000; 104():135-41. PubMed ID: 11713811
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [Activation of suppressor cells of the delayed hypersensitivity response in BALB/c mice infected or immunized with Leishmania mexicana pifanoi].
    Pérez HA; Henriquez M; de la Rosa M
    Mem Inst Oswaldo Cruz; 1985; 80(4):429-38. PubMed ID: 2943969
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Adjuvant effect of Taenia crassiceps glycans against leishmanial antigens in mice infected with Leishmania mexicana.
    Dissanayake S; Shahin A; Ameen AM
    Mol Immunol; 2005 Aug; 42(12):1495-502. PubMed ID: 15950742
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Identification and characterization of new Leishmania promastigote surface antigens, LaPSA-38S and LiPSA-50S, as major immunodominant excreted/secreted components of L. amazonensis and L. infantum.
    Bras-Gonçalves R; Petitdidier E; Pagniez J; Veyrier R; Cibrelus P; Cavaleyra M; Maquaire S; Moreaux J; Lemesre JL
    Infect Genet Evol; 2014 Jun; 24():1-14. PubMed ID: 24614507
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Genetic background influences immune responses and disease outcome of cutaneous L. mexicana infection in mice.
    Rosas LE; Keiser T; Barbi J; Satoskar AA; Septer A; Kaczmarek J; Lezama-Davila CM; Satoskar AR
    Int Immunol; 2005 Oct; 17(10):1347-57. PubMed ID: 16141242
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Distinct immunological states in murine cutaneous leishmaniasis by immunising with different amounts of antigen: the generation of beneficial, potentially harmful, harmful and potentially extremely harmful states.
    Bretscher PA; Ogunremi O; Menon JN
    Behring Inst Mitt; 1997 Feb; (98):153-9. PubMed ID: 9382736
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Induction of partial protection against Leishmania donovani by promastigote antigens in negatively charged liposomes.
    Afrin F; Anam K; Ali N
    J Parasitol; 2000 Aug; 86(4):730-5. PubMed ID: 10958448
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Comparative assessment of a DNA and protein Leishmania donovani gamma glutamyl cysteine synthetase vaccine to cross-protect against murine cutaneous leishmaniasis caused by L. major or L. mexicana infection.
    Campbell SA; Alawa J; Doro B; Henriquez FL; Roberts CW; Nok A; Alawa CB; Alsaadi M; Mullen AB; Carter KC
    Vaccine; 2012 Feb; 30(7):1357-63. PubMed ID: 22210224
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Enhanced efficacy and immunogenicity of 78kDa antigen formulated in various adjuvants against murine visceral leishmaniasis.
    Nagill R; Kaur S
    Vaccine; 2010 May; 28(23):4002-12. PubMed ID: 20093205
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Prophylactic immunization against experimental leishmaniasis. III. Protection against fatal Leishmania tropica infection induced by irradiated promastigotes involves Lyt-1+2- T cells that do not mediate cutaneous DTH.
    Liew FY; Howard JG; Hale C
    J Immunol; 1984 Jan; 132(1):456-61. PubMed ID: 6228580
    [TBL] [Abstract][Full Text] [Related]  

  • 33. T-cell responses to immunodominant LACK antigen do not play a critical role in determining susceptibility of BALB/c mice to Leishmania mexicana.
    Torrentera FA; Glaichenhaus N; Laman JD; Carlier Y
    Infect Immun; 2001 Jan; 69(1):617-21. PubMed ID: 11119565
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Efficacy of the vaccination of C57BL/6 mice against infection with different species of Leishmania].
    Monjour L; Ogunkolade W; Pointet P; Vouldoukis I
    C R Acad Sci III; 1985; 301(18):803-6. PubMed ID: 3936605
    [TBL] [Abstract][Full Text] [Related]  

  • 35. β-Adrenergic blockade protects BALB/c mice against infection with a small inoculum of Leishmania mexicana mexicana (LV4).
    García-Miss Mdel R; Mut-Martín MC; Góngora-Alfaro JL
    Int Immunopharmacol; 2015 Jan; 24(1):59-67. PubMed ID: 25461918
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Phage-fused epitopes from Leishmania infantum used as immunogenic vaccines confer partial protection against Leishmania amazonensis infection.
    Costa LE; Chávez-Fumagalli MA; Martins VT; Duarte MC; Lage DP; Lima MI; Pereira NC; Soto M; Tavares CA; Goulart LR; Coelho EA
    Parasitology; 2015 Sep; 142(10):1335-47. PubMed ID: 26099574
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Antigenic variation in Leishmania mexicana following infection of immunized mice leads to relative sparing of suppressor determinants.
    Gorczynski RM
    Immunol Lett; 1990 Jun; 24(3):155-8. PubMed ID: 1696562
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Protection against Leishmania major infection in genetically susceptible BALB/c mice by gp63 delivered orally in attenuated Salmonella typhimurium (AroA- AroD-).
    Xu D; McSorley SJ; Chatfield SN; Dougan G; Liew FY
    Immunology; 1995 May; 85(1):1-7. PubMed ID: 7635511
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Membrane glycoprotein M-2 protects against Leishmania amazonensis infection.
    Champsi J; McMahon-Pratt D
    Infect Immun; 1988 Dec; 56(12):3272-9. PubMed ID: 3182080
    [TBL] [Abstract][Full Text] [Related]  

  • 40. CXCL10/gamma interferon-inducible protein 10-mediated protection against Leishmania amazonensis infection in mice.
    Vasquez RE; Soong L
    Infect Immun; 2006 Dec; 74(12):6769-77. PubMed ID: 16982826
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.